

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

RainMed

Rainmed Medical Limited

潤邁德醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2297)

VOLUNTARY ANNOUNCEMENT

Inclusion of Coronary Angiography-derived Fractional Flow Reserve System (“caFFR System”) and Coronary Angiography-derived Index of Microvascular Resistance System (“caIMR System”) into the Chinese Expert Consensus on Computation of Coronary Physiological Assessment Technology

The board of directors (the “**Board**”) of Rainmed Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the core products of the Group, caFFR System and caIMR System, are included into the Chinese Expert Consensus on Computation of Coronary Physiological Assessment Technology (《中國計算冠狀動脈生理學檢測技術專家共識》) (the “**Expert Consensus**”).

In China, the consensus of clinical experts is mostly led by the academic team of a branch of medical association or an expert, spearheading a team of experts to reach a consensus on the diagnosis and treatment of certain clinical problems or diseases, with the aim of providing clinical medical members with instructive suggestions on a specific clinical problem, thereby reducing clinical errors and medical costs, and improving the quality and safety of medical services. The Expert Consensus was co-authored by renowned cardiology experts across the country, led by Professor Ge Junbo from Zhongshan Hospital of Fudan University (復旦大學附屬中山醫院), an academican of the Chinese Academy of Sciences (中國科學院). The Expert Consensus will fill the gap of the lack of guidance and norm in the clinical application of physiological indicators calculation in the intervention of coronary heart disease in China, and will provide a basis for its standardized application and expansion of the scope of application.

Pursuant to the Expert Consensus, caFFR System avoids the need for wires and vasodilators to carry out coronary functional assessment. It is simple to operate and easy to learn, which saves measurement time, broadens the applicable population and reduces technical risks. Numerous clinical evidence has demonstrated the diagnostic accuracy, clinical indications and prognosis value of the caFFR System, and more clinical evidence will continue to emerge. With the accumulation

of clinical evidence, caFFR System is expected to replace wire measurement FFR as a regular means to guide revascularization, and promote the popularization and application of functional assessment of myocardial ischemia in China and abroad. Meanwhile, as the global leading non-interventional micro circulation lesion diagnosis and treatment system, caIMR System has achieved a breakthrough in non-invasive quantitative evaluation of microvascular functions. The joint diagnosis of caFFR System and caIMR System allows quantitative evaluation of myocardial ischemia caused by epicardial coronary stenosis or microarterial lesions and corresponding treatment decisions, which will promote the development of coronary intervention precision medicine.

As at the date of this announcement, the Company is amongst the first to have commercially-launched coronary angiography-derived FFR systems in China. Our proprietary caFFR System has obtained both certificates of CE Mark in Europe and National Medical Products Administration (國家藥品監督管理局) approval in China, the system can achieve an accuracy rate of 95.7%, which is the highest accuracy rate among all domestic FFR measurement products. We are developing our caIMR System, which is the only less-invasive IMR measurement product having completed a confirmatory clinical trial globally and is expected to become the first less-invasive IMR system approved for commercialization globally.

The Board believes that the inclusion of caFFR System and caIMR System into the Expert Consensus represents that the above products have been highly recognized by many domestic experts in clinical applications and will significantly increase the penetration rate of these products in relevant indications, thereby injecting momentum into the long-term growth of the Company.

This announcement is made by the Company on a voluntary basis.

Cautionary Statement: The Company cannot guarantee the future prospects of caFFR System and the eventual success in the commercialization of caIMR System. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Rainmed Medical Limited
Huo Yunfei
Chairman of the Board and Executive Director

Hong Kong, December 28, 2022

As at the date of this announcement, the Board comprises Mr. Huo Yunfei, Mr. Lyu Yonghui, Mr. Zhang Liang and Ms. Gu Yang as executive directors, Mr. Wang Lin and Mr. Heng Lei as non-executive directors, and Mr. Liu Shuen Kong, Mr. Li Ho Man and Mr. Lau Tsz Ho Tony as independent non-executive directors.